Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings CorpfiledCriticalIncyte Holdings Corp
Publication of AR125919A2publicationCriticalpatent/AR125919A2/en
La presente invención se refiere a formulaciones de liberación sostenida y formas de dosificación de ruxolitinib o su sal farmacéuticamente aceptable, que son útiles en el tratamiento de enfermedades relacionadas con las quinasa Janus como trastornos mieloproliferativos.The present invention relates to sustained release formulations and dosage forms of ruxolitinib or its pharmaceutically acceptable salt, which are useful in the treatment of Janus kinase-related diseases such as myeloproliferative disorders.
ARP220101336A2012-11-152022-05-19
SUSTAINED-RELEASE RUXOLITINIB DOSAGE FORMS
AR125919A2
(en)
Substituted bicyclic compounds; pharmaceutical composition that includes them; and use in the treatment of diseases such as cancer, Alzheimer's, AIDS, among others.